Restricted accessResearch articleFirst published online 2019-2
Human Wharton's Jelly Mesenchymal Stem Cells Show Unique Gene Expression Compared with Bone Marrow Mesenchymal Stem Cells Using Single-Cell RNA-Sequencing
Human Wharton's jelly stem cells (hWJSCs) isolated from the human umbilical cord are a unique population of mesenchymal stem cells (MSCs) with significant clinical utility. Their broad differentiation potential, high rate of proliferation, ready availability from discarded cords, and prolonged maintenance of stemness properties in culture make them an attractive alternative source of MSCs with therapeutic value compared with human bone marrow MSCs (hBMMSCs). We aimed to characterize the differences in gene expression profiles between these two stem cell types using single-cell RNA sequencing (scRNA-Seq) to determine which pathways are involved in conferring hWJSCs with their unique properties. We identified 436 significantly differentially expressed genes between the two cell types, playing roles in processes, including immunomodulation, angiogenesis, wound healing, apoptosis, antitumor activity, and chemotaxis. Expression of immune molecules is particularly high in hWJSCs compared with hBMMSCs. These differences in gene expression may help to explain many of the advantages that hWJSCs have over hBMMSCs for clinical application. Although cell surface protein marker expression indicates that isolated hWJSCs and hBMMSCs are both homogenous populations, using scRNA-Seq we can clearly identify extreme variability in expression levels between individual cells within a certain cell type. If the cells are examined as bulk populations, it is not possible to appreciate that a single cell may be making a major unique contribution to the apparent overall expression level. We demonstrated how the fine tuning of expression within hWJSCs and hBMMSCs may be achieved by expression of molecules with opposing function between two cells. We hypothesize that a greater understanding of these differences in gene expression between the two cell types may aid in the development of new therapies using hWJSCs.
Get full access to this article
View all access options for this article.
References
1.
BakshD, YaoR and TuanRS. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells, 25:1384–1392.
2.
RaoMS and MattsonMP. (2001). Stem cells and aging: expanding the possibilities. Mech Ageing Dev, 122:713–734.
3.
SubramanianA, FongCY, BiswasA and BongsoA. (2015). Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton's jelly compartment provides the best source of clinically utilizable mesenchymal stem cells. PLoS One, 10:e0127992.
4.
FongCY, SubramanianA, BiswasA and BongsoA. (2016). Freezing of fresh Wharton's jelly from human umbilical cords yields high post-thaw mesenchymal stem cell numbers for cell-based therapies. J Cell Biochem, 117:815–827.
5.
PrasannaS and JahnaviV. (2011). Wharton's jelly mesenchymal stem cells as off-the-shelf cellular therapeutics: a closer look into their regenerative and immunomodulatory properties. Open Tissue End Regen Med J, 4:28–38.
6.
FanCG, ZhangQJ and ZhouJR. (2011). Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev, 7:195–207.
7.
GauthamanK, FongCY, SuganyaCA, SubramanianA, BiswasA, ChoolaniM and BongsoA. (2012). Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells. Reprod Biomed Online, 24:235–246.
8.
WangY, HanZB, MaJ, ZuoC, GengJ, GongW, SunY, LiH, WangB, et al. (2012). A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Stem Cells Dev, 21:1401–1408.
9.
WuKH, ChanCK, TsaiC, ChangYH, SieberM, ChiuTH, HoM, PengCT, WuHP and HuangJL. (2011). Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation, 91:1412–1416.
10.
ChenH, ZhangN, LiT, GuoJ, WangZ, YangM and GaoL. (2012). Human umbilical cord Wharton's jelly stem cells: immune property genes assay and effect of transplantation on the immune cells of heart failure patients. Cell Immunol, 276:83–90.
11.
SpaethEL, DembinskiJL, SasserAK, WatsonK, KloppA, HallB, AndreeffM and MariniF. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 4:e4992.
12.
ZhangT, LeeYW, RuiYF, ChengTY, JiangXH and LiG. (2013). Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther, 4:70.
13.
SubramanianA, Shu-UinG, Kae-SiangN, GauthamanK, BiswasA, ChoolaniM, BongsoA and Chui-YeeF. (2012). Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J Cell Biochem, 113:1886–1895.
14.
ZhangZ, LinH, ShiM, XuR, FuJ, LvJ, ChenL, LvS, LiY, et al. (2012). Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol, 27(Suppl 2):112–120.
15.
LvYT, ZhangY, LiuM, QiuwaxiJN, AshwoodP, ChoSC, HuanY, GeRC, ChenXW, et al. (2013). Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med, 11:196.
16.
FongCY, TamK, CheyyatraivendranS, GanSU, GauthamanK, ArmugamA, JeyaseelanK, ChoolaniM, BiswasA and BongsoA. (2014). Human Wharton's jelly stem cells and its conditioned medium enhance healing of excisional and diabetic wounds. J Cell Biochem, 115:290–302.
17.
TamK, CheyyatraviendranS, VenugopalJ, BiswasA, ChoolaniM, RamakrishnaS, BongsoA and FongCY. (2014). A nanoscaffold impregnated with human wharton's jelly stem cells or its secretions improves healing of wounds. J Cell Biochem, 115:794–803.
18.
AyuzawaR, DoiC, RachakatlaRS, PyleMM, MauryaDK, TroyerD and TamuraM. (2009). Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett, 280:31–37.
19.
ChaoKC, YangHT and ChenMW. (2012). Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization. J Cell Mol Med, 16:1803–1815.
20.
DzoboK, VogelsangM, ThomfordNE, DandaraC, KallmeyerK, PepperMS and ParkerMI. (2016). Wharton's jelly-derived mesenchymal stromal cells and fibroblast-derived extracellular matrix synergistically activate apoptosis in a p21-dependent mechanism in WHCO1 and MDA MB 231 cancer cells in vitro. Stem Cells Int, 2016:4842134.
21.
GauthamanK, FongCY, ArularasuS, SubramanianA, BiswasA, ChoolaniM and BongsoA. (2013). Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice. J Cell Biochem, 114:366–377.
22.
KalamegamG, PushparajPN, KhanF, SaitKH, AnfinanN and Al-QahtaniM. (2015). Primary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): mapping probable mechanisms and targets using systems oncology. Bioinformation, 11:529–534.
23.
LinHD, FongCY, BiswasA, ChoolaniM and BongsoA. (2014). Human Wharton's jelly stem cells, its conditioned medium and cell-free lysate inhibit the growth of human lymphoma cells. Stem Cell Rev, 10:573–586.
24.
LiuJ, HanG, LiuH and QinC. (2013). Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling. PLoS One, 8:e62844.
25.
MaY, HaoX, ZhangS and ZhangJ. (2012). The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat, 133:473–485.
26.
MauryaDK, DoiC, KawabataA, PyleMM, KingC, WuZ, TroyerD and TamuraM. (2010). Therapy with un-engineered naive rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. BMC Cancer, 10:590.
27.
RachakatlaRS, MariniF, WeissML, TamuraM and TroyerD. (2007). Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther, 14:828–835.
28.
SunB, YuKR, BhandariDR, JungJW, KangSK and KangKS. (2010). Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation. Cancer Lett, 296:178–185.
29.
WuS, JuGQ, DuT, ZhuYJ and LiuGH. (2013). Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS One, 8:e61366.
30.
FongCY, ChakLL, BiswasA, TanJH, GauthamanK, ChanWK and BongsoA. (2011). Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev, 7:1–16.
31.
NekantiU, RaoVB, BahirvaniAG, JanM, ToteyS and TaM. (2010). Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Stem Cells Dev, 19:117–130.
32.
GantaC, ChiyoD, AyuzawaR, RachakatlaR, PyleM, AndrewsG, WeissM, TamuraM and TroyerD. (2009). Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res, 69:1815–1820.
33.
LinHD, BongsoA, GauthamanK, BiswasA, ChoolaniM and FongCY. (2013). Human Wharton's jelly stem cell conditioned medium enhances freeze–thaw survival and expansion of cryopreserved CD34+ cells. Stem Cell Rev, 9:172–183.
34.
GauthamanK, YeeFC, CheyyatraivendranS, BiswasA, ChoolaniM and BongsoA. (2012). Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem, 113:2027–2039.
35.
HsiehJY, WangHW, ChangSJ, LiaoKH, LeeIH, LinWS, WuCH, LinWY and ChengSM. (2013). Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One, 8:e72604.
36.
RajA and van OudenaardenA. (2008). Nature, nurture, or chance: stochastic gene expression and its consequences. Cell, 135:216–226.
37.
LiJ, KlughammerJ, FarlikM, PenzT, SpittlerA, BarbieuxC, BerishviliE, BockC and KubicekS. (2016). Single-cell transcriptomes reveal characteristic features of human pancreatic islet cell types. EMBO Rep, 17:178–187.
38.
TreutleinB, BrownfieldDG, WuAR, NeffNF, MantalasGL, EspinozaFH, DesaiTJ, KrasnowMA and QuakeSR. (2014). Reconstructing lineage hierarchies of the distal lung epithelium using single-cell RNA-seq. Nature, 509:371–375.
39.
XinY, KimJ, NiM, WeiY, OkamotoH, LeeJ, AdlerC, CavinoK, MurphyAJ, et al. (2016). Use of the Fluidigm C1 platform for RNA sequencing of single mouse pancreatic islet cells. Proc Natl Acad Sci U S A, 113:3293–3298.
40.
ShalekAK, SatijaR, ShugaJ, TrombettaJJ, GennertD, LuD, ChenP, GertnerRS, GaublommeJT, et al. (2014). Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature, 510:363–369.
41.
FongCY, SubramanianA, BiswasA, GauthamanK, SrikanthP, HandeMP and BongsoA. (2010). Derivation efficiency, cell proliferation, freeze–thaw survival, stem-cell properties and differentiation of human Wharton's jelly stem cells. Reprod Biomed Online, 21:391–401.
42.
PicelliS, BjörklundÅK, FaridaniOR, SagasserS, WinbergG and SandbergR. (2013). Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods, 10:1096–1098.
43.
LangmeadB and SalzbergSL. (2012). Fast gapped-read alignment with Bowtie 2. Nat Methods, 9:357–359.
LiB and DeweyCN. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12:323.
46.
LoveMI, HuberW and AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15:550.
47.
AlexaA and RahnenfuhrerJ. (2016). topGO: Enrichment Analysis for Gene Ontology. R package version 2.30.0. https://bioconductor.statistik.tu-dortmund.de/packages/3.6/Boix/html/topGO.html accessed February1, 2018.
48.
BenjaminiY, DraiD, ElmerG, KafkafiN and GolaniI. (2001). Controlling the false discovery rate in behavior genetics research. Behav Brain Res, 125:279–284.
49.
LiberzonA, BirgerC, ThorvaldsdóttirH, GhandiM, MesirovJP and TamayoP. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst, 1:417–425.
50.
SubramanianA, TamayoP, MoothaVK, MukherjeeS, EbertBL, GilletteMA, PaulovichA, PomeroySL, GolubTR, LanderES and MesirovJP. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102:15545–15550.
51.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopDJ and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
52.
NabaA, ClauserKR, HoerschS, LiuH, CarrSA and HynesRO. (2012). The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics, 11:M111.014647.
53.
KalluriR and NeilsonEG. (2003). Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest, 112:1776–1784.
54.
LeopoldPL, VincentJ and WangH. (2012). A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol, 22:471–483.
55.
OshioT, KomineM, TsudaH, TominagaSI, SaitoH, NakaeS and OhtsukiM. (2017). Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci, 85:106–114.
56.
KimSH, HanSY, AzamT, YoonDY and DinarelloCA. (2005). Interleukin-32: a cytokine and inducer of TNFalpha. Immunity, 22:131–142.
57.
NajarM, RaicevicG, JebbawiF, De BruynC, MeulemanN, BronD, ToungouzM and LagneauxL. (2012). Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett, 146:50–56.
58.
KuramochiM, FukuharaH, NobukuniT, KanbeT, MaruyamaT, GhoshHP, PletcherM, IsomuraM, OnizukaM, et al. (2001). TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet, 27:427–430.
59.
EshkindL, TianQ, SchmidtA, FrankeWW, WindofferR and LeubeRE. (2002). Loss of desmoglein 2 suggests essential functions for early embryonic development and proliferation of embryonal stem cells. Eur J Cell Biol, 81:592–598.
60.
BrennanD, HuY, JoubehS, ChoiYW, Whitaker-MenezesD, O'BrienT, UittoJ, RodeckU and MahoneyMG. (2007). Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci, 120:758–771.
61.
BarkhoBZ, SongH, AimoneJB, SmrtRD, KuwabaraT, NakashimaK, GageFH and ZhaoX. (2006). Identification of astrocyte-expressed factors that modulate neural stem/progenitor cell differentiation. Stem Cells Dev, 15:407–421.
62.
ClossEI, MurrayAB, SchmidtJ, SchönA, ErfleV and StraussPG. (1990). c-fos Expression precedes osteogenic differentiation of cartilage cells in vitro. J Cell Biol, 111:1313–1323.
63.
YooKH, JangIK, LeeMW, KimHE, YangMS, EomY, LeeJE, KimYJ, YangSK, et al. (2009). Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol, 259:150–156.
64.
LiuSC, ChuangSM, HsuCJ, TsaiCH, WangSW and TangCH. (2014). CTGF increases vascular endothelial growth factor-dependent angiogenesis in human synovial fibroblasts by increasing miR-210 expression. Cell Death Dis, 5:e1485.
65.
HanahanD and FolkmanJ. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86:353–364.
66.
KaluzaD, KrollJ, GesierichS, ManavskiY, BoeckelJN, DoebeleC, ZelentA, RössigL, ZeiherAM, et al. (2013). Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arterioscler Thromb Vasc Biol, 33:533–543.
67.
ReisFM, LuisiS, CarneiroMM, CobellisL, FedericoM, CamargosAF and PetragliaF. (2004). Activin, inhibin and the human breast. Mol Cell Endocrinol, 225:77–82.
68.
WetterauLA, MooreMG, LeeKW, ShimML and CohenP. (1999). Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab, 68:161–181.
69.
RajahR, NachajonRV, CollinsMH, HakonarsonH, GrunsteinMM and CohenP. (1999). Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. Am J Respir Cell Mol Biol, 20:199–208.
OhY, MüllerHL, LamsonG and RosenfeldRG. (1993). Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem, 268:14964–14971.
72.
HartML, RuschE, KauppM, NieseltK and AicherWK. (2017). Expression of desmoglein 2, desmocollin 3 and plakophilin 2 in placenta and bone marrow-derived mesenchymal stromal cells. Stem Cell Rev, 13:258–266.
73.
KlingemannH, MatzilevichD and MarchandJ. (2008). Mesenchymal stem cells—sources and clinical applications. Transfus Med Hemother, 35:272–277.
74.
BillingAM, Ben HamidaneH, DibSS, CottonRJ, BhagwatAM, KumarP, HayatS, YousriNA, GoswamiN, et al. (2016). Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers. Sci Rep, 6:21507.
75.
JohnsonJL, NajorNA and GreenKJ. (2014). Desmosomes: regulators of cellular signaling and adhesion in epidermal health and disease. Cold Spring Harb Perspect Med, 4:a015297.
76.
HuberO and PetersenI. (2015). 150th Anniversary Series: desmosomes and the Hallmarks of Cancer. Cell Commun Adhes, 22:15–28.
77.
LinDH, BiswasA, ChoolaniM, FongCY and BongsoA. (2017). Induction of immunogenic cell death in lymphoma cells by Wharton's jelly mesenchymal stem cell conditioned medium. Stem Cell Rev, 13:801–816.
78.
GhazanfariR, ZacharakiD, LiH, Ching LimHC, SonejiS and SchedingS. (2017). Human primary bone marrow mesenchymal stromal cells and their in vitro progenies display distinct transcriptional profile signatures. Sci Rep, 7:10338.
79.
BhartiD, ShivakumarSB, ParkJK, UllahI, SubbaraoRB, ParkJS, LeeSL, ParkBW and RhoGJ. (2018). Comparative analysis of human Wharton's jelly mesenchymal stem cells derived from different parts of the same umbilical cord. Cell Tissue Res, 372:51–65.
80.
PollenAA, NowakowskiTJ, ChenJ, RetallackH, Sandoval-EspinosaC, NicholasCR, ShugaJ, LiuSJ, OldhamMC, et al. (2015). Molecular identity of human outer radial glia during cortical development. Cell, 163:55–67.
81.
MacoskoEZ, BasuA, SatijaR, NemeshJ, ShekharK, GoldmanM, TiroshI, BialasAR, KamitakiN, et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell, 161:1202–1214.
82.
KleinAM, MazutisL, AkartunaI, TallapragadaN, VeresA, LiV, PeshkinL, WeitzDA and KirschnerMW. (2015). Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell, 161:1187–1201.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
